AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29241084
Drug: Capecitabine 825
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m² combined with sorafenib and radiotherapy (45 Gy in 25 fractions over 5 weeks)
Trial: 29241084
Drug: Phase I
RxNorm normalized name: Nuvelle TS Phase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I study to establish maximum tolerated dose
Trial: 29241979
Drug: Acalabrutinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib (100 mg twice per day)
Trial: 29242852
Drug: Nonmyeloablative mMUD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative mMUD BMT with high-dose posttransplantation cyclophosphamide (PTCy)
Trial: 29243075
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin q.d. for 8 weeks
Trial: 29243168
Drug: Symptoms of
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptoms of metastatic prostate cancer and treatment side effects
Trial: 29243222
Drug: Durvalumab (anti-PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (anti-PD-L1 monoclonal antibody)
Trial: 29243287
Drug: Dabrafenib 300
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 300 mg BID
Trial: 29243287
Drug: Dabrafenib 300
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 300 mg
Trial: 29243546
Drug: Cancer therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer therapy
Trial: 29243546
Drug: Long-term prevention
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term prevention medications
Trial: 29243546
Drug: Heart medication/anti-hypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart medication/anti-hypertensives
Trial: 29243796
Drug: Myo-inositol pre-treatment
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo-inositol pre-treatment in women undergoing IVF
Trial: 29244957
Drug: ENPP1 mutation
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENPP1 mutation treatment (specific intervention details not provided)
Trial: 29245310
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg qd) plus Irinotecan (340 mg/m or 125 mg/m depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles, followed by maintenance with apatinib.
Trial: 29246128
Drug: Maternal 25(OH)D
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal 25(OH)D concentration during pregnancy (≥ 80 nmol/L)
Trial: 29246128
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test results
Trial: 29246150
Drug: Low-dose lymphocyte
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lymphocyte immunotherapy
Trial: 29246151
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (primary CVD prevention)
Trial: 29246151
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (secondary CVD prevention)
Trial: 29246803
Drug: Venetoclax (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (starting at 20 mg per day with stepwise dose ramp-up over 5 weeks to 400 mg per day; accelerated dosing schedule for rapidly progressing disease to 400 mg per day by week 3)
Trial: 29246900
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with AMT-060 (AAV5 vector with liver-specific promoter)
Trial: 29246909
Drug: Ultimaster drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultimaster drug-eluting stent
Trial: 29246916
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ticagrelor without stenting for ≤1 month
Trial: 29247021
Drug: Ulixertinib (BVD-523)
RxNorm normalized name: BVdU
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulixertinib (BVD-523) at a recommended phase II dose (RP2D) of 600 mg twice daily
Trial: 29247063
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and systemic tracer of vascular endothelial growth factor A
Trial: 29247830
Drug: AUY922 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUY922 (70 mg/m weekly intravenous)
Trial: 29248236
Drug: Bipolar androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar androgen therapy (BAT) with intramuscular testosterone cipionate 400 mg every 28 days until progression and continued luteinising hormone-releasing hormone agonist therapy.
Trial: 29248236
Drug: Rechallenge with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rechallenge with oral enzalutamide 160 mg daily after progression on BAT.
Trial: 29249180
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine
Trial: 29249202
Drug: Model projections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model projections with 30% treatment coverage (TC) rate
Trial: 29250743
Drug: Early tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early tapering of immunosuppressive agents
Trial: 29250743
Drug: Routine tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine tapering of immunosuppressive agents
Trial: 29251556
Drug: Ambrisentan and
RxNorm normalized name: ambrisentan and tadalafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan and tadalafil combination therapy
Trial: 29252124
Drug: M6620 (ATR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M6620 (ATR inhibitor) + Topotecan (1.25 mg/m²)
Trial: 29253081
Drug: Cohort A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: Four cycles of dose-dense doxorubicin and cyclophosphamide, followed by 12 doses of standard paclitaxel plus four cycles of trastuzumab and pertuzumab.
Trial: 29253081
Drug: Cohort A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: Pertuzumab, trastuzumab, and chemotherapy.
Trial: 29253081
Drug: Cohort B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort B: Pertuzumab, trastuzumab, and chemotherapy.
Trial: 29253097
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg) plus Lamivudine (300 mg)
Trial: 29254506
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interleukin-2 therapy (IL-2)
Trial: 29254856
Drug: Single fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fraction of multi-catheter interstitial high-dose rate brachytherapy (16 Gy)
Trial: 29255413
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lifestyle ± metformin without intervention)
Trial: 29257710
Drug: PT2385 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT2385 at 800 mg twice per day (RP2D)
Trial: 29258560
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (4 hours each weekday for 10 treatment days)
Trial: 29258618
Drug: Autologous tumor-derived
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor-derived autophagosome vaccine (DRibbles)
Trial: 29258674
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus ipilimumab followed by surgery
Trial: 29258674
Drug: Standard preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preoperative chemotherapy (platinum doublet regimen) followed by surgery
Trial: 29259073
Drug: Panitumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (6 mg/kg IV every 14 days)
Trial: 29260460
Drug: Second-line antidiabetic
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line antidiabetic treatment
Trial: 29260603
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach, 12 sessions, twice a week, with an additional session for parents' orientation.
Trial: 29261402
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Trial: 29261402
Drug: Oral bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bronchodilator inhalation with salbutamol 2.5 mg/ipratropium bromide 500 μg solution
Trial: 29263019
Drug: Ranolazine (500-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (500-1000 mg twice a day)
Trial: 29263061
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) in subjects with chronic kidney disease
Trial: 29263061
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under dialysis conditions
Trial: 29263061
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg glecaprevir and 120 mg pibrentasvir (single doses) under nondialysis conditions
Trial: 29263070
Drug: Alalevonadifloxacin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alalevonadifloxacin (1,000 mg twice daily for 5 days)
Trial: 29264930
Drug: No extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No extended treatment
Trial: 29268758
Drug: Pamphlet provided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamphlet provided by reception staff addressing barriers and enablers to registration, along with an Internet-enabled tablet for registration.
Trial: 29269796
Drug: Intravenous pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pentamidine at 4 mg/kg (maximum 300 mg)
Trial: 29270208
Drug: Proactive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive telephone support (daily calls initiated by a breastfeeding support team)
Trial: 29270487
Drug: Fresolimumab 1
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresolimumab 1 mg/kg
Trial: 29270487
Drug: Fresolimumab 4
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresolimumab 4 mg/kg
Trial: 29270685
Drug: BoNT-A treatment
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT-A treatment
Trial: 29270781
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg maximum dose)
Trial: 29270787
Drug: FDG PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG PET/CT at baseline (PET0), after induction (PET-AI), and end of treatment (PET-EoT)
Trial: 29272364
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) dose-escalation cohort, 1.8 mg/kg IV every 3 weeks for two cycles, escalated to 2.4 mg/kg for patients with stable disease or partial response.
Trial: 29272364
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) standard/fixed-dose cohort.
Trial: 29272443
Drug: Monthly DHA-PQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly DHA-PQ (2880 mg PQ)
Trial: 29272443
Drug: Weekly DHA-PQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly DHA-PQ (960 mg PQ)
Trial: 29272443
Drug: Low-dose daily
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose daily DHA-PQ (320 or 160 mg PQ)
Trial: 29272443
Drug: Low daily
RxNorm normalized name: SODIUM FLUORIDE 2.43 mg in 1 g DENTAL PASTE, DENTIFRICE [Auraglow Daily]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low daily DHA-PQ dosing
Trial: 29273054
Drug: NG12-1 vasoconstrictor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG12-1 vasoconstrictor, applied topically, 30 daily treatments before radiotherapy.
Trial: 29273054
Drug: Control area
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control area (no treatment).
Trial: 29274193
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 6 weeks
Trial: 29274193
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 8 weeks
Trial: 29274193
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events reported in 63.2% of patients (43/68), mainly grade 1/2, none led to treatment discontinuation.
Trial: 29275146
Drug: Ciprofloxacin, levofloxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, levofloxacin, or fosfomycin (antibiotic prophylaxis)
Trial: 29275946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of specific ECG abnormalities
Trial: 29276022
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.2 mg/kg or 1.8 mg/kg) plus bendamustine (70 mg/m2)
Trial: 29276022
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg) plus bendamustine (80 mg/m2)
Trial: 29276625
Drug: Epicardial transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicardial transplantation of atrial appendage micrografts in a fibrin gel covered with a tissue-engineered ECM sheet
Trial: 29277374
Drug: Aphasia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphasia therapy with aerobic exercise via bicycle ergometer (n = 5)
Trial: 29277374
Drug: Aphasia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphasia therapy with stretching (n = 2)
Trial: 29277374
Drug: Aphasia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphasia therapy alone (Block 1)
Trial: 29279281
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.5 mL PCV13 in previously vaccinated subjects (n=284)
Trial: 29279281
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of 0.5 mL PCV13 in previously vaccinated subjects (n=288)
Trial: 29280355
Drug: 50, 125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50, 125, 300, or 600 mg of testosterone enanthate weekly injections
Trial: 29280355
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg dutasteride daily
Trial: 29280762
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.2 mg/kg with AVD (doxorubicin, vinblastine, dacarbazine)
Trial: 29281086
Drug: Antiplatelet (AP)
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet (AP) monotherapy
Trial: 29281086
Drug: Anticoagulant (AC)
RxNorm normalized name: CPDA-1 Anticoagulant
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant (AC) monotherapy
Trial: 29281086
Drug: AP monotherapy
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP monotherapy
Trial: 29281086
Drug: AC monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC monotherapy
Trial: 29281086
Drug: AP +
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP + AC and no antithrombotic therapy
Trial: 29282024
Drug: Emotion regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion regulation individual therapy (ERITA) for 12 weeks
Trial: 29282032
Drug: Riociguat adjusted
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid
Trial: 29282090
Drug: Tofacitinib (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5.0 mg BID for Cohort 1, 2.5 mg BID for Cohort 2, 3.0 mg BID for Cohort 3)
Trial: 29282090
Drug: Tofacitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (oral solution, grape flavor)
Trial: 29282090
Drug: Tofacitinib (multiple-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (multiple-dose, twice daily for 5 days)
Trial: 29282099
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for six months
Trial: 29282271
Drug: Low-dose chest
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chest CT (LDCT) during yearly screening rounds for 3 years plus a 1-year follow-up.
Trial: 29282676
Drug: Ambrisentan (Volibris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (Volibris tablet 2.5 mg)
Trial: 29284010
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg administered every 2 weeks for up to 2 years or until disease progression/unacceptable toxicity
Trial: 29284510
Drug: Low-dose, prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, prophylactic naloxone infusion
Trial: 29285038
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and Gemcitabine (Neoadjuvant Chemotherapy)
Trial: 29285668
Drug: Cabazitaxel 20
RxNorm normalized name: cabazitaxel 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 20 mg/m² administered in second-(or later) setting, median of two cycles.
Trial: 29391382
Drug: bDMARD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bDMARD treatment
Trial: 29288237
Drug: Genomics-driven precision
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomics-driven precision medicine
Trial: 29288911
Drug: Perampanel secondary
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel secondary monotherapy
Trial: 29288911
Drug: Perampanel adjunctive
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel adjunctive treatment
Trial: 29289757
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy
Trial: 29290515
Drug: Fixed airflow
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed airflow obstruction (FAO) defined as post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity ≤70%
Trial: 29292064
Drug: DREAMS 2G
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DREAMS 2G (drug-eluting absorbable metal scaffold)
Trial: 29292843
Drug: Ontuxizumab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontuxizumab at 12 mg/kg
Trial: 29293893
Drug: Fosmidomycin-piperaquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin-piperaquine (30 mg/kg twice daily for fosmidomycin and 16 mg/kg once daily for piperaquine for 3 days)
Trial: 29296710
Drug: Epstein-Barr virus
RxNorm normalized name: Epstein-Barr virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epstein-Barr virus (EBV) DNA in cell-free blood 8 days after initiation of therapy